PCM
AMED

Pentwater Capital Management’s Amedisys AMED Stock Holding History

Pentwater Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,715,084
Closed -$169M – 111
2025
Q2 		$169M Buy
1,715,084
+370,084
+28% +$35M 1.09% 19
2025
Q1 		$125M Buy
1,345,000
+165,000
+14% +$15.2M 1.05% 20
2024
Q4 		$107M Buy
1,180,000
+105,000
+10% +$9.64M 1.18% 20
2024
Q3 		$104M Buy
1,075,000
+293,741
+38% +$28.7M 1.07% 21
2024
Q2 		$71.7M Buy
781,259
+141,259
+22% +$13.1M 0.92% 24
2024
Q1 		$59M Sell
640,000
-140,000
-18% -$13.1M 0.6% 27
2023
Q4 		$74.1M Sell
780,000
-364,000
-32% -$34M 0.83% 29
2023
Q3 		$107M Buy
1,144,000
+807,000
+239% +$74.6M 0.57% 18
2023
Q2 		$30.8M Buy
+337,000
New +$27.6M 0.21% 46

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pentwater Capital Management's AMED Position: Q3 2025 in Review

Pentwater Capital Management sold out of Amedisys (AMED) in Q3 2025, closing a stake of 1,715,084 shares — an estimated $169M sold.

Pentwater Capital Management first reported a position in AMED in Q2 2023 and held it in 9 quarters. The position peaked at $169M in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Pentwater Capital Management reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Pentwater Capital Management sold 1,715,084 Amedisys shares in Q3 2025, an estimated $169M.
  • Pentwater Capital Management first reported a position in Amedisys in Q2 2023 and held it in 9 quarters.
  • Pentwater Capital Management's Amedisys position peaked at $169M in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Pentwater Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.